Heptares moves to Welwyn BioPark and plans further expansion

20-May-2009 - United Kingdom

Heptares Therapeutics Ltd announced that it is relocating to the BioPark in Welwyn Garden City, between London and Cambridge, from its laboratories in Mill Hill, North London, where it has been based since founding in 2007. The new facility provides office and laboratory space and will enable Heptares to meet its future growth requirements following the successful raising of £21 million in a Series A fundraising completed in February 2009. The Company currently has 15 employees and is aiming to more than double employee numbers over the next year.

Heptares’ CEO, Dr Malcolm Weir, said: “Heptares has progressed rapidly since 2007, and the new funds we raised earlier this year have given us a very good opportunity to implement our strategy for generating new drug candidates to highly validated but previously challenging GPCRs. We are pleased to move to the Welwyn BioPark, which provides a first-class research environment within easy reach of London and Cambridge, where we retain excellent scientific links.”

The Company’s new address as from 12 May 2008 is:

Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances